Recently, AusperBio (Ausper Biopharma Co., Ltd. and AusperBio Therapeutics, Inc.) has completed a Pre-A+ round of financing worth 100 million yuan. This round of financing was contributed by the investors from the Pre-A round, and the funds were closed in U.S. dollars in the middle of this year.
It is reported that this round of financing will help accelerate the advancement of global clinical trials for AHB-137 under AusperBio and the research and development of other Med-Oligo™ small nucleic acid innovative drugs with targeted delivery.
In October 2022, AusperBio completed a Pre-A round of financing totaling approximately 16 million US dollars, with participation from institutional investor InnoPinnacle Fund. The company's angel round investors continued to show confidence and increased their investment in this round.
Dr. Guozheng Cheng, Founder & CEO of AusperBio, stated: "This Pre-A+ round of financing coincides with the efficient progress of the global clinical trials for AHB-137. The swift completion of this round enables the AusperBio team to consolidate resources, thereby advancing clinical trials for AHB-137 simultaneously in China, the United States, and other countries and regions, accelerating efficacy studies in patients with chronic hepatitis B. Additionally, this round of financing will significantly expedite innovative breakthroughs in the Med-Oligo™ small nucleic acid drug platform technology, achieving more efficient intrahepatic and extrahepatic targeted therapies to address broader and unmet clinical needs."
AusperBio is a clinical-stage innovative drug development company operating simultaneously in China and the United States, committed to developing First-in-class and Best-in-class proprietary targeted delivery small nucleic acid drugs. AusperBio owns the proprietary intellectual property Med-Oligo™ ASO patent technology platform, focusing on functional cures for chronic hepatitis B (HBV) and highly efficient targeted treatments for liver diseases, while expanding its exploration of significant potential in new targets beyond the liver. AusperBio's strategy is to combine its leading Med-Oligo™ oligonucleotide technology with specific and highly efficient targeting technologies to address a wide range of currently unmet medical needs.
AHB-137, a naked antisense oligonucleotide (ASO) with the potential to become a cornerstone for functional cure of chronic hepatitis B, is the first innovative drug from AusperBio's self-developed Med-Oligo™ platform to enter clinical trials. Its excellent preclinical data garnered significant attention at the 2023 EASL™ (European Association for the Study of the Liver) conference.
Currently, AHB-137 is undergoing clinical trials simultaneously in multiple countries and regions, including New Zealand, China, and the United States. Through a global layout, it aims to accelerate the goal of achieving functional cure for hepatitis B.